O. Yin

发表

Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants

H. Schran, C. Tanaka, O. Yin, 2011, Journal of clinical pharmacology.

Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial

E. Antman, R. Giugliano, E. Braunwald, 2018, Circulation.

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors

W. Tap, J. Healey, H. Gelderblom, 2020, Journal of clinical pharmacology.

A Mechanism-Based Population Pharmacokinetic Model for Characterizing Time-Dependent Pharmacokinetics of Midostaurin and its Metabolites in Human Subjects

H. Schran, O. Yin, Yanfeng Wang, 2008, Clinical pharmacokinetics.

First‐in‐Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS‐1040, an Inhibitor of the Activated Form of Thrombin‐Activatable Fibrinolysis Inhibitor, in Healthy Subjects

O. Yin, F. Kobayashi, G. Atiee, 2019, Journal of clinical pharmacology.

Pharmacokinetics of acetaminophen in Hong Kong Chinese subjects.

A. Chow, B. Tomlinson, M. Chow, 2001, International journal of pharmaceutics.

Liquid chromatography-tandem mass spectrometry method for the determination of tranexamic acid in human plasma.

M. Chow, O. Yin, Q. Chang, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies.

M. Chow, O. Yin, Sherry S L Lam, 2004, Rapid communications in mass spectrometry : RCM.

Effect of Grapefruit Juice on the Pharmacokinetics of Nilotinib in Healthy Participants

N. Gallagher, H. Schran, O. Yin, 2010, Journal of clinical pharmacology.

Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.

E. Antman, R. Giugliano, E. Braunwald, 2019, Journal of the American College of Cardiology.

Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β‐hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese

B. Tomlinson, S. Chan, O. Yin, 2016, Journal of clinical pharmacy and therapeutics.

CYP3A5 but Not CYP2D6 Polymorphism Contributes Significantly to the Variability in Dextropropoxyphene Disposition

B. Tomlinson, M. Chow, O. Yin, 2010, Journal of clinical pharmacology.

CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects

B. Tomlinson, M. Chow, O. Yin, 2005, Clinical pharmacology and therapeutics.

Population Pharmacokinetics of Cyclosporine in Chinese Cardiac Transplant Recipients

M. Chow, O. Yin, Sophia Lau, 2006, Pharmacotherapy.

Variability in Renal Clearance of Substrates for Renal Transporters in Chinese Subjects

B. Tomlinson, M. Chow, O. Yin, 2006, Journal of clinical pharmacology.

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

E. Antman, R. Giugliano, E. Braunwald, 2021, Circulation.

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

R. Larson, R. Clark, H. Kantarjian, 2011, European Journal of Clinical Pharmacology.

Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min

O. Yin, M. Kotsuma, M. Grosso, 2021, Clinical pharmacology in drug development.

Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia

A. Krämer, N. Russell, G. Martinelli, 2020, Journal of clinical pharmacology.

Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.

W. Zhou, N. Gallagher, H. Schran, 2009, Clinical therapeutics.

Population Pharmacokinetics and Dose–Exposure Proportionality of Edoxaban in Healthy Volunteers

Raymond Miller, O. Yin, 2014, Clinical Drug Investigation.

Dose‐ and Time‐Dependent Pharmacokinetics of Midostaurin in Patients With Diabetes Mellitus

H. Schran, O. Yin, J. Kisicki, 2008, Journal of clinical pharmacology.

Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.

Zhi-xiang Shen, E. Leroy, H. Schran, 2008, British journal of clinical pharmacology.

Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway

P. Hu, N. Parrott, O. Yin, 2015, European Journal of Clinical Pharmacology.

Effect of multidrug resistance gene-1 (ABCB1) polymorphisms on the single-dose pharmacokinetics of cloxacillin in healthy adult Chinese men.

B. Tomlinson, M. Chow, O. Yin, 2009, Clinical therapeutics.

Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin.

B. Tomlinson, O. Yin, Miao Hu, 2013, Drug metabolism and pharmacokinetics.

Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia

M. Baccarani, H. Kantarjian, F. Giles, 2012, European Journal of Clinical Pharmacology.

Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients.

Jianxiang Wang, P. Hu, O. Yin, 2009, Clinical therapeutics.

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia

A. Krämer, N. Russell, G. Martinelli, 2021, Cancer Chemotherapy and Pharmacology.

NO CLINICALLY RELEVANT PHARMACOKINETIC INTERACTION BETWEEN AMBRISENTAN AND SILDENAFIL

H. Ghofrani, O. Yin, M. Gerber, 2006 .

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors

T. Garimella, F. LaCreta, K. Yoshihara, 2020, Clinical pharmacology and therapeutics.

Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

H. Kantarjian, T. Smith, F. Giles, 2010, Clinical pharmacology and therapeutics.

Phenotype-genotype Relationship and Clinical Effects of Citalopram in Chinese Patients

Y. Wing, Y. Cheung, M. Chow, 2006, Journal of clinical psychopharmacology.

A first‐in‐human study of DS‐1040, an inhibitor of the activated form of thrombin‐activatable fibrinolysis inhibitor, in healthy subjects

O. Yin, G. Atiee, J. Zhou, 2017, Journal of thrombosis and haemostasis : JTH.

Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole.

M. Waye, A. Chow, B. Tomlinson, 2004, Pharmacogenetics.

Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults

D. Yim, E. Capparelli, O. Yin, 2018, Therapeutic drug monitoring.

Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene‐Dose Effect and Intrasubject Variability

A. Chow, B. Tomlinson, O. Yin, 2004, Journal of clinical pharmacology.

OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine

Brian Tomlinson, B. Tomlinson, M. Chow, 2008, Pharmacogenetics and genomics.

Incorporating Pharmacogenomics in Drug Development: A Perspective from Industry

O. Yin, 2013 .

Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.

E. Antman, S. Connolly, R. Giugliano, 2021, Journal of the American College of Cardiology.

Abstract P6-17-10: Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses

J. Baselga, H. Iwata, K. Tamura, 2019, Poster Session Abstracts.

The KIT Tyrosine Kinase Inhibitor Midostaurine (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis (ASM): Interim Results of a Phase II Trial.

T. Graubert, C. Corless, T. George, 2007 .

Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia

R. Larson, M. Baccarani, H. Kantarjian, 2012, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

R. Larson, R. Clark, H. Kantarjian, 2012, European Journal of Clinical Pharmacology.

Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan

H. Iwata, K. Tamura, J. Watanabe, 2021, Clinical pharmacology and therapeutics.

Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE‐AF study.

H. Heidbuchel, C. Morillo, S. Hohnloser, 2018, Clinical cardiology.

Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma.

M. Chow, O. Yin, Xiaojin Shi, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

EFFECT OF CYP2D6*10 ALLELE ON THE PHARMACOKINETICS OF LORATADINE IN CHINESE SUBJECTS

B. Tomlinson, X. Shi, M. Chow, 2005, Drug Metabolism and Disposition.

Simultaneous determination of paracetamol and dextropropoxyphene in human plasma by liquid chromatography/tandem mass spectrometry: application to clinical bioequivalence studies.

M. Chow, O. Yin, Sherry S L Lam, 2005, Rapid communications in mass spectrometry : RCM.

Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model‐informed Drug Development Strategy

F. LaCreta, O. Yin, H. Zahir, 2023, Clinical pharmacology in drug development.

Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway

P. Hu, N. Parrott, O. Yin, 2015, European Journal of Clinical Pharmacology.

Pharmacokinetics and Modeling of Quercetin and Metabolites

Z. Zuo, M. Chow, O. Yin, 2005, Pharmaceutical Research.

Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin

Raymond Miller, O. Yin, K. Truitt, 2016, Journal of clinical pharmacology.

Omeprazole limited sampling strategies to predict area under the concentration–time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping

M. Ingelman-Sundberg, R. Baldwin, D. Yim, 2011, European Journal of Clinical Pharmacology.

Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia

M. Baccarani, H. Kantarjian, F. Giles, 2013, European Journal of Clinical Pharmacology.

Omeprazole limited sampling strategies to predict area under the concentration–time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping

M. Ingelman-Sundberg, R. Baldwin, D. Yim, 2012, European Journal of Clinical Pharmacology.

Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.

J. Mestan, P. Manley, O. Yin, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia.

J. Mestan, P. Manley, O. Yin, 2009 .

Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects

B. Tomlinson, S. Chan, O. Yin, 2012, Drug metabolism and drug interactions.

Effect of the Proton Pump Inhibitor Esomeprazole on the Oral Absorption and Pharmacokinetics of Nilotinib

W. Zhou, G. Golor, N. Gallagher, 2010, Journal of clinical pharmacology.

CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects

B. Tomlinson, S. Chan, M. Chow, 2013, European Journal of Clinical Pharmacology.

Effects of Yogurt and Applesauce on the Oral Bioavailability of Nilotinib in Healthy Volunteers

G. Golor, H. Schran, O. Yin, 2011, Journal of clinical pharmacology.

Effects of Nilotinib on Single-Dose Warfarin Pharmacokinetics and Pharmacodynamics

G. Golor, E. Leroy, N. Gallagher, 2011, Clinical drug investigation.

Edoxaban population pharmacokinetics and exposure–response analysis in patients with non-valvular atrial fibrillation

Raymond Miller, O. Yin, Kimura Tetsuya, 2014, European Journal of Clinical Pharmacology.

Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers

W. Zhou, O. Yin, S. Novick, 2012, Cancer Chemotherapy and Pharmacology.

Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects

B. Tomlinson, M. Chow, O. Yin, 2012, European Journal of Clinical Pharmacology.

Interindividual and Intraindividual Variability of the Urinary 6β‐Hydroxycortisol/Cortisol Ratio in Chinese Subjects: Implications of Its Use for Evaluating CYP3A Activity

B. Tomlinson, M. Chow, O. Yin, 2004, Journal of clinical pharmacology.